A2 Bio Highlights Tmod™ CAR T-Cell Progress at 2024 SITC Annual Meeting

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing innovative logic-gated cell therapies to selectively target tumor cells while sparing normal cells, today presented updates on its Tmod™ CAR T-cell clinical programs at the 39th Annual Meeting of…









